Biogen Inc. Files 8-K on Financials
Ticker: BIIB · Form: 8-K · Filed: 2024-08-01T00:00:00.000Z
Sentiment: neutral
Topics: financial-reporting, 8-k
Related Tickers: BIIB
TL;DR
Biogen dropped an 8-K on Aug 1st detailing their financials. Check it out.
AI Summary
Biogen Inc. filed an 8-K on August 1, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits related to the period ending August 1, 2024. Biogen Inc. is a Delaware-incorporated company specializing in biological products.
Why It Matters
This filing provides an update on Biogen's financial performance and condition, which is crucial for investors to assess the company's health and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not indicate any unusual or significant risks.
Key Players & Entities
- BIOGEN INC. (company) — Registrant
- August 1, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 225 Binney Street, Cambridge, Massachusetts 02142 (address) — Principal executive offices
- 617-679-2000 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Biogen Inc.'s Results of Operations and Financial Condition, and to include Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on August 1, 2024.
In which state is Biogen Inc. incorporated?
Biogen Inc. is incorporated in Delaware.
What is Biogen Inc.'s principal executive office address?
Biogen Inc.'s principal executive office is located at 225 Binney Street, Cambridge, Massachusetts 02142.
What is the SIC code for Biogen Inc.?
The Standard Industrial Classification (SIC) code for Biogen Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 497 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-08-01 06:55:02
Key Financial Figures
- $0.0005 — ange on which registered Common Stock, $0.0005 par value BIIB The Nasdaq Global Select
Filing Documents
- biib-20240801.htm (8-K) — 24KB
- exhibit991-q22024pressrele.htm (EX-99.1) — 545KB
- newbiogenlogo.jpg (GRAPHIC) — 3KB
- 0000875045-24-000022.txt ( ) — 730KB
- biib-20240801.xsd (EX-101.SCH) — 2KB
- biib-20240801_lab.xml (EX-101.LAB) — 21KB
- biib-20240801_pre.xml (EX-101.PRE) — 12KB
- biib-20240801_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On August 1, 2024, Biogen Inc. issued a press release announcing its results of operations and financial condition for the second quarter ended June 30, 2024. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The press release is being furnished pursuant to Item 2.02 of this Current Report on Form 8-K and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that Section, nor shall such document be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits The exhibits listed below are furnished as part of this Current Report on Form 8-K. Exhibit No. Description 99.1 Biogen's press release dated August 1, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOGEN INC. By: /s/ Wendell Taylor Wendell Taylor Secretary Date: August 1, 2024